Management of Patients with Low-Grade Gliomas

Neurologic Clinics

Volumn 25, Issue 4, 2007, Pages 1073-1088

  Gilbert, Mark R ^a   Lang, Frederick F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; CARBAMAZEPINE; DEXAMETHASONE; GEFITINIB; IMATINIB; IRINOTECAN; LAMOTRIGINE; LEVITERACTAM; LOMUSTINE; PACLITAXEL; PHENOBARBITAL; PHENYTOIN; PROCARBAZINE; TEMOZOLOMIDE; TIPIFARNIB; TOPIRAMATE; UNCLASSIFIED DRUG; VALPROIC ACID; VINCRISTINE;

ADJUVANT THERAPY; BONE MARROW TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER INFILTRATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CLINICAL ARTICLE; CLINICAL TRIAL; CONSCIOUSNESS LEVEL; GLIOMA; HEADACHE; HISTOLOGY; HUMAN; INTRACRANIAL HYPERTENSION; LEUKOPENIA; META ANALYSIS; MOLECULAR BIOLOGY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT CARE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE; REVIEW; SEIZURE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; WORLD HEALTH ORGANIZATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; DIAGNOSIS, DIFFERENTIAL; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; PROGNOSIS; RADIOTHERAPY DOSAGE; TOMOGRAPHY, X-RAY COMPUTED;

EID: 35348992044     PISSN: 07338619     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ncl.2007.07.007     Document Type: Review

References (52)

1. In: Kleihues P., and Cavenee W.K. (Eds). Pathology and genetics of tumours of the nervous system (2000), IARC Press, Lyon (France)
2. Vertosick Jr. F.T., Selker R.G., and Arena V.C. Survival of patients with well-differentiated astrocytomas diagnosed in the era of computed tomography. Neurosurgery 28 4 (1991) 496-501
3. McCormack B.M., Miller D.C., Budzilovich G.N., et al. Treatment and survival of low-grade astrocytoma in adults-1977-1988. Neurosurgery 31 4 (1992) 636-642 [discussion: 642]
4. Henson J.W., and Gonzalez R.G. Neuroimaging in glioma therapy. Expert Rev Neurother 4 4 (2004) 665-671
5. Cairncross G., Berkey B., Shaw E., et al. A phase III trial of chemotherapy plus radiotherapy (RT) versus RT alone for pure and mixed anaplastic oligodendroglioma (RTOG 9402): an intergroup trial by the RTOG, NCCTG, SWOG, NCIC CTG and ECOG. J Clin Oncol 80 (2006) 27-35
6. van den Bent M.J., Carpentier A.F., Brandes A.A., et al. Adjuvant PCV improves progression free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized EORTC phase III trial. J Clin Oncol (2006)
7. Ohgaki H., and Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J Neuropathol Exp Neurol 64 6 (2005) 479-489
8. Jenkins R.B., Blair H., Ballman K.V., et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66 20 (2006) 9852-9861
9. Aldape K., Burger P.C., and Perry A. Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131 2 (2007) 242-251
10. Okamoto Y., Di Patre P.L., Burkhard C., et al. Population-based study on incidence, survival rates, and genetic alterations of low-grade diffuse astrocytomas and oligodendrogliomas. Acta Neuropathol (Berl) 108 1 (2004) 49-56
11. Pignatti F., van den Bent M., Curran D., et al. Prognostic factors for survival in adult patients with cerebral low-grade glioma. J Clin Oncol 20 8 (2002) 2076-2084
12. Bauman G., Lote K., Larson D., et al. Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis. Int J Radiat Oncol Biol Phys 45 4 (1999) 923-929
13. Maiuri F., Del Basso De Caro M.L., Iaconetta G., et al. Prognostic and survival-related factors in patients with well-differentiated oligodendrogliomas. Zentralbl Neurochir 67 4 (2006) 204-209
14. Omuro A.M., Leite C.C., Mokhtari K., et al. Pitfalls in the diagnosis of brain tumours. Lancet Neurol 5 11 (2006) 937-948
15. Gilbert M.R., Supko J.G., Batchelor T., et al. Phase I clinical and pharmacokinetic study of irinotecan in adults with recurrent malignant glioma. Clin Cancer Res 9 8 (2003) 2940-2949
16. Newton H.B., Goldlust S.A., and Pearl D. Retrospective analysis of the efficacy and tolerability of levetiracetam in brain tumor patients. J Neurooncol 78 1 (2006) 99-102
17. Glantz M.J., Cole B.F., Forsyth P.A., et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 54 10 (2000) 1886-1893
18. Lang F.F., Olansen N.E., DeMonte F., et al. Surgical resection of intrinsic insular tumors: complication avoidance. J Neurosurg 95 4 (2001) 638-650
19. Sawaya R., Hammoud M., Schoppa D., et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 42 5 (1998) 1044-1055 [discussion: 1055-6]
20. Jackson R.J., Fuller G.N., Abi-Said D., et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro oncol 3 3 (2001) 193-200
21. Hall W., and Truwit C. 1.5 T Spectroscopy-supported brain biopsy. Neurosurg Clin N Am 16 (2005) 165-172
22. Ammirati M., Vick N., Liao Y.L., et al. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 21 2 (1987) 201-206
23. Stummer W., Novotny A., Stepp H., et al. Fluorescence-guided resection of glioblastoma multiforme by using 5-aminolevulinic acid-induced porphyrins: a prospective study in 52 consecutive patients. J Neurosurg 93 6 (2000) 1003-1013
24. Vuorinen V., Hinkka S., Farkkila M., et al. Debulking or biopsy of malignant glioma in elderly people-a randomised study. Acta Neurochir (Wien) 145 1 (2003) 5-10
25. Janny P., Cure H., Mohr M., et al. Low grade supratentorial astrocytomas. Management and prognostic factors. Cancer 73 7 (1994) 1937-1945
26. Leighton C., Fisher B., Bauman G., et al. Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation. J Clin Oncol 15 4 (1997) 1294-1301
27. Shibamoto Y., Kitakabu Y., Takahashi M., et al. Supratentorial low-grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables. Cancer 72 1 (1993) 190-195
28. Berger M.S., Deliganis A.V., Dobbins J., et al. The effect of extent of resection on recurrence in patients with low grade cerebral hemisphere gliomas. Cancer 74 6 (1994) 1784-1791
29. Claus E.B., Horlacher A., Hsu L., et al. Survival rates in patients with low-grade glioma after intraoperative magnetic resonance image guidance. Cancer 103 6 (2005) 1227-1233
30. Yeh S.A., Ho J.T., Lui C.C., et al. Treatment outcomes and prognostic factors in patients with supratentorial low-grade gliomas. Br J Radiol 78 927 (2005) 230-235
31. Keles G.E., Lamborn K.R., and Berger M.S. Low-grade hemispheric gliomas in adults: a critical review of extent of resection as a factor influencing outcome. J Neurosurg 95 5 (2001) 735-745
32. Karim A.B., Maat B., Hatlevoll R., et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. Int J Radiat Oncol Biol Phys 36 3 (1996) 549-556
33. Shaw E., Arusell R., Scheithauer B., et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group study. J Clin Oncol 20 9 (2002) 2267-2276
34. Karim A.B., Afra D., Cornu P., et al. Randomized trial on the efficacy of radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study 22845 with the Medical Research Council study BRO4: an interim analysis. Int J Radiat Oncol Biol Phys 52 2 (2002) 316-324
35. van den Bent M.J., Afra D., de Witte O., et al. Long-term efficacy of early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 366 9490 (2005) 985-990
36. Heimans J.J., and Taphoorn M.J. Impact of brain tumour treatment on quality of life. J Neurol 249 8 (2002) 955-960
37. Meyers C.A., and Brown P.D. Role and relevance of neurocognitive assessment in clinical trials of patients with CNS tumors. J Clin Oncol 24 8 (2006) 1305-1309
38. Armstrong T.S., Mendoza T.R., Gring I., et al. Validation of the M.D., Anderson Symptom Inventory Brain Tumor Module (MDASI-BT). J Neurooncol (2006) in press
39. Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-defined gross total resection of adult supratentorial low-grade glioma. Submitted for publication 2007.
40. Eyre H.J., Crowley J.J., Townsend J.J., et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for incompletely resected low-grade gliomas: a Southwest Oncology Group study. J Neurosurg 78 6 (1993) 909-914
41. Buckner J.C., Gesme Jr. D., O'Fallon J.R., et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J Clin Oncol 21 2 (2003) 251-255
42. Soffietti R., Ruda R., Bradac G.B., et al. PCV chemotherapy for recurrent oligodendrogliomas and oligoastrocytomas. Neurosurgery 43 5 (1998) 1066-1073
43. Quinn J.A., Reardon D.A., Friedman A.H., et al. Phase II trial of temozolomide in patients with progressive low-grade glioma. J Clin Oncol 21 4 (2003) 646-651
44. Pace A., Vidiri A., Galie E., et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and radiological response. Ann Oncol 14 12 (2003) 1722-1726
45. van den Bent M.J., Chinot O., Boogerd W., et al. Second-line chemotherapy with temozolomide in recurrent oligodendroglioma after PCV (procarbazine, lomustine and vincristine) chemotherapy: EORTC Brain Tumor Group phase II study 26972. Ann Oncol 14 4 (2003) 599-602
46. Lang F.F., and Gilbert M.R. Diffusely infiltrative low-grade gliomas in adults. J Clin Oncol 24 8 (2006) 1236-1245
47. Hoang-Xuan K., Capelle L., Kujas M., et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 22 15 (2004) 3133-3138
48. Brada M., Viviers L., Abson C., et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II gliomas. Ann Oncol 14 12 (2003) 1715-1721
49. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N Engl J Med 352 10 (2005) 997-1003
50. Everhard S., Kaloshi G., Criniere E., et al. MGMT methylation: a marker of response to temozolomide in low-grade gliomas. Ann Neurol 60 6 (2006) 740-743
51. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352 10 (2005) 987-996
52. Chamberlain M.C., Glantz M.J., Chalmers L., et al. Early necrosis following concurrent Temodar and radiotherapy in patients with glioblastoma. J Neurooncol 82 1 (2007) 81-83